Mycovia Pharmaceuticals, Inc. Announces First Participant Enrolled in an Investigator-Initiated Phase 2 Study for Cryptococcal Meningitis
Cryptococcal meningitis is a serious fungal infection causing an estimated 112,000 deaths annually The PLATFORM-CM trial is evaluating oteseconazole and other investigational products against the standard of care for treating cryptococcal meningitis Mycovia Pharmaceuticals, Inc. (“Mycovia”) has announced enrollment of the first participant in an investigator-initiated clinical trial evaluating oteseconazole and other investigational products for […]